摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-cyanomethyl-6H-indolo(2,3-b)quinoxaline | 111756-84-4

中文名称
——
中文别名
——
英文名称
6-cyanomethyl-6H-indolo(2,3-b)quinoxaline
英文别名
2-Indolo[3,2-b]quinoxalin-6-ylacetonitrile
6-cyanomethyl-6H-indolo(2,3-b)quinoxaline化学式
CAS
111756-84-4
化学式
C16H10N4
mdl
MFCD03035435
分子量
258.282
InChiKey
DLFBQGAOONYSEM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    20
  • 可旋转键数:
    1
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.06
  • 拓扑面积:
    54.5
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Substituted indoloquinoxalines
    摘要:
    通式I的吲哚喹喔啉衍生物,其中R.sub.1代表1-4个相似或不同的取代基之一,在位置1-4和/或7-10,选择自卤素,优选溴,碳原子不超过4个的低烷基/烷氧基团,三氟甲基团,三氯甲基团;X是一个基团--(CH.sub.2).sub.n--R.sub.2,在其中R.sub.2代表氮含基团,如NH.sub.2,NHR.sub.4或NR.sub.5 R.sub.6,其中R.sub.4,R.sub.5和R.sub.6独立地是低烷基或环烷基,n是1到4的整数,R.sub.3代表氢,碳原子不超过4个的低烷基/环烷基团,以及所述化合物与酸和卤素加合物的生理上可接受的加合物,优选与碘,一氯化碘或溴化碘的加合物。还描述了通过将通式II的化合物与含有残基--CHR.sub.3 R.sub.7的反应性化合物反应或通过加热重排通式III的化合物来制备所述化合物的方法。新型吲哚喹喔啉具有抗病毒作用和对抗癌症的作用。
    公开号:
    US04990510A1
点击查看最新优质反应信息

文献信息

  • Indoloquinoxalines with substituents in 6-position containing cyclic
    申请人:Lundblad; Lief
    公开号:US04916124A1
    公开(公告)日:1990-04-10
    Novel indoloquinoxalines having substituents in 6-position containing cyclic groups, of the general formula I ##STR1## wherein R.sub.1 represents hydrogen or one or several preferably 1 to 4, similar or different substituents in the positions 1-4 and/or 7-10, selected from halogen, lower alkyl-/alkoxy group having not more than 4 carbon atoms, trifluoromethyl group, trichloromethyl group; X is a group ##STR2## wherein Y is CH.sub.2, NH, O or S and a is 2, 3 or 4 and wherein also the bond --C.dbd.N-- can be saturated; Z is alkyl having 1-6 carbon atoms, Cl, Br or CF.sub.3 and R.sub.3 represents hydrogen, lower alkyl-/cycloalkyl group having not more than 4 carbon atoms, and the physiologically acceptable addition products of the compounds with acids and halogen adducts are described. Also methods for preparing said compounds by reaction of a compound of the formula II ##STR3## with a reactive compound containing the residue --CHR.sub.3 X or by rearranging a compound of the formula III ##STR4## by heating, are described. The novel indoloquinoxalines have antiviral effect and have effect against cancer.
    具有6位取代基的环状羰基吲哚喹啉类新化合物,其一般式为I,其中R.sub.1代表氢或一个或几个在位置1-4和/或7-10处选择的卤素、不超过4个碳原子的低烷基/烷氧基基团、三甲基基团、三甲基基团等类似或不同的取代基;X是一个基团,其中Y是CH.sub.2、NH、O或S,a为2、3或4,且其中键--C.dbd.N--可以饱和;Z是1-6个碳原子的烷基、Cl、Br或CF.sub.3,R.sub.3代表氢、不超过4个碳原子的低烷基/环烷基基团,所述化合物与酸和卤素加合物的生理可接受的加合物也得到描述。还描述了通过将式II的化合物与含有残基--CHR.sub.3 X的反应性化合物进行反应或通过加热重排式III的化合物来制备所述化合物的方法。这些新型羰基吲哚喹啉具有抗病毒作用和抗癌作用。
  • [EN] ALKYL SUBSTITUTED INDOLOQUINOXALINES<br/>[FR] INDOLOQUINOXALINES ALKYL-SUBSTITUEES
    申请人:OXYPHARMA AB
    公开号:WO2005123741A1
    公开(公告)日:2005-12-29
    Novel substituted indoloquinoxalines of formula (I R2 (I) Y Wherein R1 is hydrogen or represents one or more similar or different substituents in the positions 7 to 10 selected from the group halogen, lower alkyl/alkoxy, hydroxy, trifluoromethyl, trichloromethyl, trifluoromethoxy, R2 represents similar or different C1-C4 alkyl substituents, X is CO or CH2, Y is OH, NH2, NH-(CH2)n-R3 wherein R3 represents lower alkyl, OH, NH2, NHR4 or NR5R6 wherein R4, R5 and R6 independently are lower alkyl or cyclo­alkyl and n is an integer of from 2 to 4, with the provision that when X is CH2, Y is OH or NH-(CH2)n-OH, and pharmacologically acceptable salts thereof are described. The compounds are useful as drugs for preventing and/or treating autoimmune diseases.
    式(I)中的新型取代吲哚喹啉化合物,其中R1表示氢原子或选自卤素、较低烷基/烷氧基、羟基、三甲基、三甲基、三甲氧基等一种或多种相似或不同的取代基,在7到10位上取代;R2表示相似或不同的C1-C4烷基取代基;X为CO或CH2;Y为OH、NH2、NH-( )n-R3,其中R3表示较低烷基、羟基、NH2、NHR4或NR5R6,其中R4、R5和R6独立地为较低烷基或环烷基,n为2到4的整数。当X为 时,Y为OH或NH-( )n-OH。还描述了药理学上可接受的盐。这些化合物可用作预防和/或治疗自身免疫性疾病的药物。
  • Alkyl substituted indoloquinoxalines
    申请人:Bergman Jan
    公开号:US20050288296A1
    公开(公告)日:2005-12-29
    Novel substituted indoloquinoxalines of formula (I wherein R 1 is hydrogen or represents one or more similar or different substituents in the positions 7 to 10 selected from the group halogen, lower alkyl/alkoxy, hydroxy, trifluoromethyl, trichloromethyl, trifluoromethoxy, R 2 represents similar or different C 1 -C 4 alkyl substituents, X is CO or CH 2 , Y is OH, NH 2 , NH—(CH 2 ) n —R 3 wherein R 3 represents lower alkyl, OH, NH 2 , NHR 4 or NR 5 R 6 wherein R 4 , R 5 and R 6 independently are lower alkyl or cyclo-alkyl and n is an integer of from 2 to 4, with the provision that when X is CH 2 , Y is OH or NH—(CH 2 ) n —OH, and pharmacologically acceptable salts thereof are described. The compounds are useful as drugs for preventing and/or treating autoimmune diseases.
    本发明涉及化学式(I)的新型取代吲哚喹啉,其中R1为氢或在7到10位上选择自卤素、较低的烷基/烷氧基、羟基、三甲基、三甲基、三甲氧基等的一个或多个类似或不同的取代基;R2代表类似或不同的C1-C4烷基取代基;X为CO或CH2;Y为OH、NH2、NH—( )n—R3,其中R3代表较低的烷基、羟基、NH2、NHR4或NR5R6,其中R4、R5和R6独立地为较低的烷基或环烷基,n为2到4的整数。但当X为 时,Y为OH或NH—( )n—OH。所述化合物及其药学上可接受的盐可用作预防和/或治疗自身免疫性疾病的药物。
  • Indoloquinoxalines with substituents in 6-position containing cyclic groups
    申请人:Lundblad, Leif
    公开号:EP0231159A1
    公开(公告)日:1987-08-05
    Novel indoloquinoxalines having substituents in 6- position containing cyclic groups, of the general formula I wherein R1 represents hydrogen or one or several preferably 1 to 4, similar or different substituents in the positions 1-4 and/or 7-10, selected from halogen, lower alkyl-/alkoxy group having not more than 4 carbon atoms, trifluoromethyl group, trichloromethyl group; X is a group wherein Y is CH2, NH, O or S and a is 2, 3 or 4 and wherein also the bond -C=N- can be saturated; Z is alkyl having 1-6 carbon atoms, Cl, Br or CF3 and R3 represents hydrogen, lower alkyl-/cykloalkyl group having not more than 4 carbon atoms, and the physiologically acceptable addition products of the compounds with acids and halogen adducts are described. Also methods for preparing said compounds by reaction of a compound of the formula II with a reactive compound containing the residue -CHR3X or by rearranging a compound of the formula III by heating, are described. · The novel indoloquinoxalines have antiviral effect and have effect against cancer.
    新型吲哚喹喔啉,其 6-位取代基含有通式 I 的环状基团 其中 R1 代表氢或在 1-4 位和/或 7-10 位上的一个或多个(最好是 1 至 4 个)相似或不同的取代基,选自卤素、不超过 4 个碳原子的低级烷基/烷氧基、三甲基、三甲基;X 是一个基团 其中 Y 是 CH2、NH、O 或 S,a 是 2、3 或 4,键 -C=N- 也可以是饱和的;Z 是具有 1-6 个碳原子的烷基、Cl、Br 或 CF3,R3 代表氢、具有不超过 4 个碳原子的低级烷基-/环烷基,并描述了这些化合物与酸和卤素加成物的生理学上可接受的加成产物。此外,还描述了通过式 II 的化合物与含有残余物 与含有残基 -CHR3X 的活性化合物反应或通过加热重排式 III 的化合物来制备上述化合物的方法。 通过加热重新排列式 III 的化合物来制备上述化合物的方法。 - 新型吲哚喹喔啉类化合物具有抗病毒和抗癌作用。
  • ALKYL SUBSTITUTED INDOLOQUINOXALINES
    申请人:Oxypharma AB
    公开号:EP1756111A1
    公开(公告)日:2007-02-28
查看更多